美国食品药品监督管理局（FDA）已正式批准利那洛肽（Linzess®）用于治疗两岁及以上年龄儿童的功能性便秘（Fc）。这一决定标志着该药物在儿科适应症上的重要扩展，为患有此类慢性消化系统疾病的低龄患者提供了一种新的治疗选择。
利那洛肽是一种鸟苷酸环化酶-C激动剂，此前已获准用于成人慢性特发性便秘和肠易激综合征伴便秘的治疗。此次针对儿科患者的批准，是基于在相应年龄组患者中进行的临床试验数据，证明了其在该人群中的安全性与有效性。
对于药品的研发方Ironwood医药而言，此次监管批准是其产品管线的一项重要进展，可能为公司开拓新的患者群体和市场机会。功能性便秘在儿童中是一种常见疾病，此次批准有望为众多受此困扰的患儿及其家庭带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.